Flexion CEO Makes The Case For Zilretta
Flexion CEO Mike Clayman shares expectations for Zilretta for knee osteoarthritis and discusses plans for commercialization in an interview at the Biotech Showcase in January.
Flexion CEO Mike Clayman shares expectations for Zilretta for knee osteoarthritis and discusses plans for commercialization in an interview at the Biotech Showcase in January.